ATE230993T1 - Pharmazeutische zusammensetzung zur behandlung von alkoholabhängigkeit, die opioid antagonisten mit nmda-rezeptorkomplex-modulatoren enthält - Google Patents

Pharmazeutische zusammensetzung zur behandlung von alkoholabhängigkeit, die opioid antagonisten mit nmda-rezeptorkomplex-modulatoren enthält

Info

Publication number
ATE230993T1
ATE230993T1 AT99916907T AT99916907T ATE230993T1 AT E230993 T1 ATE230993 T1 AT E230993T1 AT 99916907 T AT99916907 T AT 99916907T AT 99916907 T AT99916907 T AT 99916907T AT E230993 T1 ATE230993 T1 AT E230993T1
Authority
AT
Austria
Prior art keywords
nmda receptor
receptor complex
pharmaceutical composition
opioid antagonists
alcohol dependence
Prior art date
Application number
AT99916907T
Other languages
English (en)
Inventor
Martine Daoust
Yves Le Buclay Bonhomme
Philippe Durbin
Original Assignee
Lipha
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lipha filed Critical Lipha
Application granted granted Critical
Publication of ATE230993T1 publication Critical patent/ATE230993T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT99916907T 1998-03-26 1999-03-26 Pharmazeutische zusammensetzung zur behandlung von alkoholabhängigkeit, die opioid antagonisten mit nmda-rezeptorkomplex-modulatoren enthält ATE230993T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP98400723A EP0945133A1 (de) 1998-03-26 1998-03-26 Pharmazeutische Zusammensetzung zur Behandlung von Alkohol- oder Drogenabhängigkeit, die Opioid Antagonisten mit NMDA-Rezeptorkomplex-Modulatoren enthält
PCT/EP1999/002337 WO1999048500A1 (en) 1998-03-26 1999-03-26 Combination for the treatment of alcohol and drug dependence containing an opioid antagonist and a nmda receptor complex modulator

Publications (1)

Publication Number Publication Date
ATE230993T1 true ATE230993T1 (de) 2003-02-15

Family

ID=8235311

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99916907T ATE230993T1 (de) 1998-03-26 1999-03-26 Pharmazeutische zusammensetzung zur behandlung von alkoholabhängigkeit, die opioid antagonisten mit nmda-rezeptorkomplex-modulatoren enthält

Country Status (18)

Country Link
US (1) US6512009B1 (de)
EP (2) EP0945133A1 (de)
KR (1) KR20010034678A (de)
AT (1) ATE230993T1 (de)
AU (1) AU758569B2 (de)
BR (1) BR9909138A (de)
CA (1) CA2325739C (de)
CZ (1) CZ296367B6 (de)
DE (1) DE69904922T2 (de)
DK (1) DK1063995T3 (de)
ES (1) ES2190205T3 (de)
HK (1) HK1032542A1 (de)
HU (1) HU226555B1 (de)
NO (1) NO319313B1 (de)
PL (1) PL193241B1 (de)
RU (1) RU2226107C2 (de)
SK (1) SK284623B6 (de)
WO (1) WO1999048500A1 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8052982B2 (en) 1998-07-20 2011-11-08 Peptech Animal Health Pty Limited Bioimplant formulation comprising lecithin and stearin
BR9912275A (pt) * 1998-07-20 2001-04-17 Peptech Ltd Formulação de bioimplante
WO2001052851A1 (en) * 2000-01-22 2001-07-26 Albert Shulman Methods for the treatment of substance abuse
EP1262196A3 (de) * 2001-05-23 2002-12-18 Pfizer Products Inc. Kombination eines Inhibitoren der Monoaminwiederaufnahme und eines Opioidanatagonisten zur Verwendung in Alkoholismus und Alkoholsucht
DE10129265A1 (de) * 2001-06-18 2003-01-02 Hf Arzneimittelforsch Gmbh Wirkstoff-Kombination zur medikamentösen Sucht- oder Rauschmitteltherapie
ES2187288B1 (es) * 2001-09-24 2004-09-16 Garbil Pharma Investigacion Chile Ltda Aminas como agentes anti-alcoholismo.
EP1509182A4 (de) 2002-05-31 2009-12-30 Titan Pharmaceuticals Inc Implantierbare polymere vorrichtung zur verzögerten freisetzung von buprenorphin
EP1575569B1 (de) 2002-12-13 2010-09-29 Durect Corporation Orale darreichungsform mit flüssigen hochviskosen trägersystemen
WO2004056337A2 (en) * 2002-12-18 2004-07-08 Pain Therapeutics Oral dosage forms with therapeutically active agents in controlled release cores and immediate release gelatin capsule coats
CN1777426A (zh) * 2003-03-31 2006-05-24 泰坦医药品公司 用于持续释放多巴胺受体激动剂的可植入聚合物装置
US20050031668A1 (en) * 2003-05-30 2005-02-10 Patel Rajesh A. Implantable polymeric device for sustained release of nalmefene
US20070099947A1 (en) * 2005-11-03 2007-05-03 Alkermes, Inc. Methods and compositions for the treatment of brain reward system disorders by combination therapy
AU2007333656A1 (en) * 2006-12-19 2008-06-26 University Of Virginia Patent Foundation Combined effects of topiramate and ondansetron on alcohol consumption
US8415401B2 (en) 2007-12-06 2013-04-09 Durect Corporation Oral pharmaceutical dosage forms
KR20100127799A (ko) 2008-02-28 2010-12-06 유니버시티 오브 버지니아 페이턴트 파운데이션 세로토닌 운반체 유전자 및 알콜중독의 치료
US20100260844A1 (en) 2008-11-03 2010-10-14 Scicinski Jan J Oral pharmaceutical dosage forms
ES2664083T3 (es) 2010-07-02 2018-04-18 University Of Virginia Patent Foundation Enfoque genético molecular para el tratamiento y diagnóstico de la dependencia de alcohol y drogas
EA027743B1 (ru) 2011-09-09 2017-08-31 Юниверсити Оф Вирджиния Пэтент Фаундейшн Молекулярно-генетический подход для лечения и диагностики алкогольной и наркотической зависимости
RU2476209C1 (ru) * 2012-02-29 2013-02-27 Станислав Анатольевич Кедик Имплантируемое лекарственное средство на основе налтрексона для лечения пациентов, зависимых от алкоголя или опиатов
CN105120659A (zh) 2013-03-15 2015-12-02 度瑞公司 用于降低溶解可变性的具有流变改性剂的组合物
GB201308440D0 (en) * 2013-05-10 2013-06-19 Dalgleish Angus Therapeutic
WO2023023038A1 (en) * 2021-08-17 2023-02-23 Yale University Treatment compositions and methods

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11505547A (ja) * 1996-03-13 1999-05-21 エール ユニバーシティ ナルトレキソン及び関連化合物を用いる禁煙処置

Also Published As

Publication number Publication date
KR20010034678A (ko) 2001-04-25
PL193241B1 (pl) 2007-01-31
DK1063995T3 (da) 2003-03-10
BR9909138A (pt) 2000-12-05
WO1999048500A1 (en) 1999-09-30
EP1063995A1 (de) 2001-01-03
HUP0101546A3 (en) 2002-10-28
EP1063995B1 (de) 2003-01-15
EP0945133A1 (de) 1999-09-29
DE69904922D1 (de) 2003-02-20
AU758569B2 (en) 2003-03-27
CZ20003525A3 (cs) 2001-04-11
CZ296367B6 (cs) 2006-02-15
SK284623B6 (sk) 2005-08-04
HUP0101546A2 (hu) 2001-09-28
HU226555B1 (en) 2009-03-30
NO20004788L (no) 2000-11-24
HK1032542A1 (en) 2001-07-27
SK14282000A3 (sk) 2001-05-10
NO319313B1 (no) 2005-07-11
CA2325739A1 (en) 1999-09-30
CA2325739C (en) 2007-05-15
PL343069A1 (en) 2001-07-30
US6512009B1 (en) 2003-01-28
AU3522699A (en) 1999-10-18
DE69904922T2 (de) 2004-01-08
NO20004788D0 (no) 2000-09-25
RU2226107C2 (ru) 2004-03-27
ES2190205T3 (es) 2003-07-16

Similar Documents

Publication Publication Date Title
ATE230993T1 (de) Pharmazeutische zusammensetzung zur behandlung von alkoholabhängigkeit, die opioid antagonisten mit nmda-rezeptorkomplex-modulatoren enthält
FI960727A (fi) Neurokiniiniantagonisteina käyttökelpoiset heterosyklit
ATE175114T1 (de) Pharmazeutische zusammensetzungen enthaltend einen opiat antagonist und calcium salze, ihre verwendung zur behandlung von endorphin- vermittelten krankheiten
DE69017302T3 (de) Zentrale Cholecystokinin-Antagonisten zur Behandlung von psychiatrischen Krankheiten.
DE69631157D1 (de) Pharmazeutische Zubereitung zur Verwendung in der Behandlung von Diabetes
AR002459A1 (es) Antagonistas de vasopresina de benzacepina triciclicos, una composicion farmaceutica que los contiene, un metodo para tratar enfermedades y unprocedimiento para su preparacion.
ATE404211T1 (de) Xenon als nmda-antogonist zur neuroprotektion
ATE308328T1 (de) Pharmazeutische zusammensetzung enthaltend clindamycin und clotrimazol, zur behandlung vaginaler infektionen
BR0311898A (pt) Tratamento de associação para depressão e ansiedade com antagonistas de nk1 e nk3
ATE221391T1 (de) Konjugat enthaltend dtpa und albumin zur individuellen dosierung von arzneimitteln
PT101444A (pt) Associacao sinergizante com efeito antagonista dos receptores nk1 e nk2, uso de produtos com actividade antagonista dos receptores nk1 e nk2 na sua preparacao e composicao farmaceutica contendo a referida associacao
ATE400563T1 (de) Neue neurokinin-antagonisten zum gebrauch als arzneimittel
PL350568A1 (en) N-(2-phenyl-4-aminobutyl)-1-naphtamides as antagonists of neurokinin 1 receptors
DE60114597D1 (de) Naphthamid-neurokinin antagonisten zur verwendung als medikamente
BR0211323A (pt) Combinação de ingredientes ativos, uso de uma combinação de ingredientes ativos e método de terapia farmacológica de dependência de nicotina
BR0311881A (pt) Combinações de inbidores de pde-v e antagonistas de nk1 para o tratamento de depressão
EA200401617A1 (ru) Комбинация nmda-антагониста и ингибиторов ацетилхолинэстеразы для лечения болезни альцгеймера
DE50212538D1 (de) Substituierte 5,6,6a,11b-tetrahydro-7-oxa-5-aza-benzoäcüfluoren-6-carbonsäurederivate als nmda-antagonisten
BR0005039A (pt) Antagonistas do receptor nk-1 e eletriptano para o tratamento da enxaqueca
DE68905343D1 (de) Dosisform zur verabreichung von calciumantagonisten.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1063995

Country of ref document: EP